GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DARA Biosciences Inc (NAS:DARA) » Definitions » ROE %

DARA Biosciences (DARA Biosciences) ROE % : -145.23% (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is DARA Biosciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. DARA Biosciences's annualized net income for the quarter that ended in Sep. 2015 was $-10.79 Mil. DARA Biosciences's average Total Stockholders Equity over the quarter that ended in Sep. 2015 was $7.43 Mil. Therefore, DARA Biosciences's annualized ROE % for the quarter that ended in Sep. 2015 was -145.23%.

The historical rank and industry rank for DARA Biosciences's ROE % or its related term are showing as below:

DARA's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.08
* Ranked among companies with meaningful ROE % only.

DARA Biosciences ROE % Historical Data

The historical data trend for DARA Biosciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DARA Biosciences ROE % Chart

DARA Biosciences Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -144.39 -196.53 -135.24 -122.67 -87.71

DARA Biosciences Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.81 -43.14 -100.56 -108.21 -145.23

Competitive Comparison of DARA Biosciences's ROE %

For the Biotechnology subindustry, DARA Biosciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DARA Biosciences's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DARA Biosciences's ROE % distribution charts can be found below:

* The bar in red indicates where DARA Biosciences's ROE % falls into.



DARA Biosciences ROE % Calculation

DARA Biosciences's annualized ROE % for the fiscal year that ended in Dec. 2014 is calculated as

ROE %=Net Income (A: Dec. 2014 )/( (Total Stockholders Equity (A: Dec. 2013 )+Total Stockholders Equity (A: Dec. 2014 ))/ count )
=-9.001/( (6.609+13.916)/ 2 )
=-9.001/10.2625
=-87.71 %

DARA Biosciences's annualized ROE % for the quarter that ended in Sep. 2015 is calculated as

ROE %=Net Income (Q: Sep. 2015 )/( (Total Stockholders Equity (Q: Jun. 2015 )+Total Stockholders Equity (Q: Sep. 2015 ))/ count )
=-10.792/( (8.692+6.17)/ 2 )
=-10.792/7.431
=-145.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2015) net income data. ROE % is displayed in the 30-year financial page.


DARA Biosciences  (NAS:DARA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2015 )
=Net Income/Total Stockholders Equity
=-10.792/7.431
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-10.792 / 4.724)*(4.724 / 10.78)*(10.78 / 7.431)
=Net Margin %*Asset Turnover*Equity Multiplier
=-228.45 %*0.4382*1.4507
=ROA %*Equity Multiplier
=-100.11 %*1.4507
=-145.23 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2015 )
=Net Income/Total Stockholders Equity
=-10.792/7.431
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-10.792 / -10.792) * (-10.792 / -10.792) * (-10.792 / 4.724) * (4.724 / 10.78) * (10.78 / 7.431)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1 * -228.45 % * 0.4382 * 1.4507
=-145.23 %

Note: The net income data used here is four times the quarterly (Sep. 2015) net income data. The Revenue data used here is four times the quarterly (Sep. 2015) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


DARA Biosciences ROE % Related Terms

Thank you for viewing the detailed overview of DARA Biosciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


DARA Biosciences (DARA Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Executives
David Drutz director, officer: Executive Chairman and CMO 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David L. Tousley officer: CFO 14610 PAWNEE LANE, LEAWOOD KS 66224
Gail Lieberman director 175 EAST 79TH STREET, APT. 4D, NEW YORK NY 10075
Paul John Richardson director 17 COUNTRY OAKS ROAD, LEBANON NJ 08833
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Ann A Rosar officer: Vice President Finance C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Geert Cauwenbergh director 1 STULTS DRIVE, PLAINSBORO NJ 08536
Kurt M Eichler director C/O SPRING BANK PHARMACEUTICALS, INC., STE S-7, MILFORD MA 01757
Hamilton Jordan director
Stuart C Mcwhorter director 113 SEABOARD LANE, FRANKLIN TN 37067
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Michael P Duffy officer: SVP, GC and Secretary C/O POINT THERAPEUTICS INC, 125 SUMMER STREET SUITE 1840, BOSTON MA 02110
Richard J Benjamin director 15 WHITE PINE ROAD, NEWTON MA 02464
Larry G Pickering director 26130 MANDEVILLA DRIVE, BONITA SPRINGS FL 34134

DARA Biosciences (DARA Biosciences) Headlines